Topics

Articles

The downside of pricing specialty pharmaceuticals too high

Why 'recall readiness' should be top-of-mind for every pharma exec

Continuing problems with compounding pharmacies muddle biopharma’s future direction

Should personalized medicine imply compromised patient safety?

Oncology is the market for today's pipeline products. Here's why the community setting needs to be preserved as a primary site of care to administer those products

Why community oncology matters

Managing the specialty pharmacy channel's evolution

In the race to improve product performance, not enough attention is paid to 'who's actually going to switch?'

Focusing pharma marketing on 'headroom'

Like the other war on drugs, there's no end in sight

The war on prescription drug abuse

When drugs in development today hit the marketplace in 2020, they will need evidence of economic and clinical value results to be commercially successful

Pharma's stake in comparative effectiveness research

Pharmaceutical marketing is now operating in a new landscape--the Economy of Attention

Liberating time in the Economy of Attention

Abbott's spinout of AbbVie offers lessons

Opinion